Shanghai-based I-Mab Biopharma Co. Ltd. became the first IPO out of the gate this year, pricing its IPO of about 7.4 million American depositary shares (ADSs) – each 10 representing 23 ordinary shares of the company, par value $0.0001 per share – at $14 each, within the planned range of $12 at the low end and $15 at the high. But the stock’s performance might not have been all investors hoped, as shares (NASDAQ:IMAB) closed at $12.50 Jan. 17.
HONG KONG – Bionetix Inc., of Suwon, South Korea, has secured ₩10.8 billion (US$9.33 million) in series B funding. The biotech, founded in February 2017, has attracted a total of KRW14.7 billion to date. The company will use the funds to advance NTX-301, a therapy for myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with epigenetic dysregulation, and NTX-101, a glaucoma treatment.
Boulder, Colo.-based startup Arpeggio Biosciences Inc. scooped up $3.2 million in seed funding in a round led by Khosla Ventures, with participation by Fundersclub, Fifty Years, TechU and Y Combinator.
Frazier Healthcare Partners closed Frazier Life Sciences X LP, the company’s third fund, by exceeding its target with more than $617 million in capital commitments in an oversubscribed fundraiser.
Albuquerque, N.M.-based Agilvax Inc. CEO Joseph Patti told BioWorld that his firm’s antibody-drug conjugate (ADC) method uses “the same linkers, same payloads” as other firms but the “unique factor for us is the target we’re going after” – SLC7A11 (xCT), an amino acid transporter implicated in the metabolic redox activities of metastatic cancer cells.
PERTH, Australia – Sydney-based Noxopharm Ltd. announced that its spin-off, Nyrada Inc., began trading on Australia’s Securities Exchange (ASX:NYR) on Jan. 16, following an oversubscribed IPO that raised AU$8.5 million (US$5.8 million).
RSS
